Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study

#3982

Introduction: After the approval of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in Japan (June 2021), its treatment experience is increasing, but limited data are available in Japanese patients with neuroendocrine neoplasm (NEN).

Aim(s): To elucidate the safety and efficacy of PRRT in a larger Japanese cohort.

Materials and methods: We retrospectively analyzed somatostatin receptor-expressing NEN patients treated with PRRT in our institution between October 2021 and November 2023.

Conference:

Presenting Author:

Authors: Okamoto K, Hijioka S, Goto Y, Honma Y, Hirano H,

Keywords: PRRT, 177Lu-DOTATATE, Japanese cohort,